# Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients

> **NCT00247494** · PHASE4 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 90 (estimated)

## Conditions studied

- HIV Infection
- Atherosclerosis

## Interventions

- **DRUG:** mycophenol mofetil (MMF, Cellcept®) 500 mg BID

## Key facts

- **NCT ID:** NCT00247494
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2009-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00247494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00247494, "Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00247494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*